136 related articles for article (PubMed ID: 11956266)
1. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.
Sondak VK; Liu PY; Tuthill RJ; Kempf RA; Unger JM; Sosman JA; Thompson JA; Weiss GR; Redman BG; Jakowatz JG; Noyes RD; Flaherty LE
J Clin Oncol; 2002 Apr; 20(8):2058-66. PubMed ID: 11956266
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Sosman JA; Unger JM; Liu PY; Flaherty LE; Park MS; Kempf RA; Thompson JA; Terasaki PI; Sondak VK;
J Clin Oncol; 2002 Apr; 20(8):2067-75. PubMed ID: 11956267
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
Eggermont AM; Suciu S; Rutkowski P; Marsden J; Santinami M; Corrie P; Aamdal S; Ascierto PA; Patel PM; Kruit WH; Bastholt L; Borgognoni L; Bernengo MG; Davidson N; Polders L; Praet M; Spatz A
J Clin Oncol; 2013 Oct; 31(30):3831-7. PubMed ID: 24019551
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.
Hersey P; Coates AS; McCarthy WH; Thompson JF; Sillar RW; McLeod R; Gill PG; Coventry BJ; McMullen A; Dillon H; Simes RJ
J Clin Oncol; 2002 Oct; 20(20):4181-90. PubMed ID: 12377961
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study.
Meyskens FL; Liu PY; Tuthill RJ; Sondak VK; Fletcher WS; Jewell WR; Samlowski W; Balcerzak SP; Rector DJ; Noyes RD
J Clin Oncol; 1994 Oct; 12(10):2060-5. PubMed ID: 7931474
[TBL] [Abstract][Full Text] [Related]
6. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
[TBL] [Abstract][Full Text] [Related]
7. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
[TBL] [Abstract][Full Text] [Related]
8. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.
Carson WE; Unger JM; Sosman JA; Flaherty LE; Tuthill RJ; Porter MJ; Thompson JA; Kempf RA; Othus M; Ribas A; Sondak VK
Cancer Immunol Res; 2014 Oct; 2(10):981-7. PubMed ID: 24994597
[TBL] [Abstract][Full Text] [Related]
10. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
Baldueva IA; Novik AV; Moiseenko VM; Nekhaeva TL; Danilova AB; Danilov AO; Protsenko SA; Petrova TIu; Uleĭskaia GI; Shchekina LA; Semenova AI; Mikhaĭlichenko TD; Teletaeva GM; Zhabina AS; Volkov NV; Komarov IuI
Vopr Onkol; 2012; 58(2):212-21. PubMed ID: 22774527
[TBL] [Abstract][Full Text] [Related]
11. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
12. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.
Harris JE; Ryan L; Hoover HC; Stuart RK; Oken MM; Benson AB; Mansour E; Haller DG; Manola J; Hanna MG
J Clin Oncol; 2000 Jan; 18(1):148-57. PubMed ID: 10623705
[TBL] [Abstract][Full Text] [Related]
14. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
15. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
[TBL] [Abstract][Full Text] [Related]
16. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma.
Blaheta HJ; Ellwanger U; Schittek B; Sotlar K; MacZey E; Breuninger H; Thelen MH; Bueltmann B; Rassner G; Garbe C
J Invest Dermatol; 2000 Apr; 114(4):637-42. PubMed ID: 10733666
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
[TBL] [Abstract][Full Text] [Related]
18. Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
Chick RC; Faries MB; Hale DF; Kemp Bohan PM; Hickerson AT; Vreeland TJ; Myers JW; Cindass JL; Brown TA; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Clifton GT; Park H; Sloan AJ; Wagner T; Peoples GE
Cancer Med; 2021 Jul; 10(13):4302-4311. PubMed ID: 33982452
[TBL] [Abstract][Full Text] [Related]
19. Sentinel-node biopsy or nodal observation in melanoma.
Morton DL; Thompson JF; Cochran AJ; Mozzillo N; Elashoff R; Essner R; Nieweg OE; Roses DF; Hoekstra HJ; Karakousis CP; Reintgen DS; Coventry BJ; Glass EC; Wang HJ;
N Engl J Med; 2006 Sep; 355(13):1307-17. PubMed ID: 17005948
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study.
Mordoh J; Kairiyama C; Bover L; Solarolo E
Medicina (B Aires); 1997; 57(4):421-7. PubMed ID: 9674264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
